Grand Pharmaceutical Group

Grand Pharmaceutical Group is an international pharmaceutical company that develops innovative drugs and medical devices across various therapeutic areas. The company integrates pharmaceutical technology, nuclear medicine for anti-tumor diagnosis and treatment, and precision interventional diagnosis and treatment for cerebro-cardiovascular diseases. Its technical approach emphasizes independent research and development, leveraging platforms like mRNA technology for anti-tumor and anti-infective drugs, and glycomics technology for antivirals, supported by global R&D centers.

Established in 1995, Grand Pharmaceutical Group has evolved into a significant player in the global healthcare landscape. While specific individual founders and their initial insights are not publicly detailed for the current corporate entity, the company’s history reflects a strategic consolidation and expansion, particularly marked by its integration into larger corporate structures, propelling its focus on innovation and global reach in healthcare solutions.

The company primarily serves patients globally through its diverse product pipeline, addressing critical medical needs such as oncology, infectious diseases, rare conditions, and cardiovascular ailments. Grand Pharmaceutical Group’s long-term vision centers on continuous transformation towards innovation and internationalization, actively exploring high-quality innovative projects to broaden its product offerings and enhance its comprehensive strengths, aiming to make a substantial impact in global health.